| Message: | 98% Dapoxetine for the Treatment of Premature Ejaculation (PE) to improve the meanintravaginal ejaculation latency time (IELT) CAS 119356-77-3
1. Quick Detail:
Product Name Dapoxetine
Alias d-Dapoxetine; DL-Dapoxetine
CAS 119356-77-3
Assay 98.0%
Appearance White Crystalline Powder
Molecular Formula C21H23NO.ClH
Molecular Weight 341.88
Grade Pharmaceutical Grade
Storage Shading, Confined Preservation
2. Product description:
Dapoxetine, marketed as Priligy and Westoxetin, among and other brands, is the first compound developed specially for the treatment of premature ejaculation (PE) in men 18–64 years old. Dapoxetine works by inhibiting theserotonin transporter, increasing serotonin's action at the post synaptic cleft, and as a consequence promoting ejaculatory delay. As a member of selective serotonin reuptake inhibitor (SSRI) family, dapoxetine was initially created as an antidepressant. However, unlike other SSRIs, dapoxetine is absorbed and eliminated rapidly in the body. Its fast acting property makes it suitable for the treatment of PE but not as an antidepressant.
3.Applications:
Randomized, double blind, placebo-controlled trials have confirmed the efficacy of dapoxetine for the treatment of PE. Different dosage has different impacts on different type of PE. Dapoxetine 60 mg significantly improves the meanintravaginal ejaculation latency time (IELT) compared to that of dapoxetine 30 mg in men with lifelong PE, but there is no difference in men with acquired PE. Dapoxetine, given 1–3 hours before sexual episode, prolongs IELT, increases the sense of control and sexual satisfaction in men of 18 to 64 years of age with PE. |
my account
